Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Aug 2;103(31):e39095.
doi: 10.1097/MD.0000000000039095.

Risks and benefits of anti-TNF therapy for ulcerative colitis in a patient with autoimmune hepatitis-related cirrhosis: Case report

Renata de Medeiros Dutra  1 , Fernanda Patrícia Jeronymo Pinto  1 , Marcela Maria Silvino Craveiro  2 , Julio Pinheiro Baima  1 , Rogerio Saad-Hossne  2 , Fernando Gomes Romeiro  1 , Ligia Yukie Sassaki  1
Affiliations
Case Reports

Risks and benefits of anti-TNF therapy for ulcerative colitis in a patient with autoimmune hepatitis-related cirrhosis: Case report

Renata de Medeiros Dutra et al. Medicine (Baltimore). .

Abstract

Rationale: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by continuous inflammation of the colonic mucosa. Autoimmune hepatitis (AIH) is a chronic liver disease characterized by hypergammaglobulinemia, circulating autoantibodies, interface hepatitis, and favorable response to immunosuppression. An association between IBD and AIH is uncommon, and experts have suggested that in patients with overlapping IBD and AIH, the anti-tumor necrosis factor agents can be used. Therefore, this study reports a rare case of a patient with liver cirrhosis due to AIH and UC refractory to conventional treatment and discusses the risks and benefits of using anti-tumor necrosis factor in both conditions.

Patient concerns: A 28-year-old female presented with symptoms of diarrhea, abdominal pain, asthenia, and inappetence, accompanied by abdominal collateral circulation, anemia, alteration of liver enzymes, and elevation of C-reactive protein levels.

Diagnoses: The patient underwent a liver biopsy, which was consistent with liver cirrhosis due to AIH. Colonoscopy showed an inflammatory process throughout the colon, compatible with moderately active UC.

Interventions: The patient received mesalazine, azathioprine, and corticotherapy, with no control of the inflammatory process. Faced with refractoriness to drug treatment and side effects of corticosteroids with an increased risk of severe infection due to cirrhosis, we opted to use infliximab for the treatment of UC. The patient presented with a clinical response and infliximab therapy was maintained.

Outcomes: Eight months after starting infliximab therapy, the patient developed pneumonia with complications from disseminated intravascular coagulation and died.

Lessons subsections: AIH is a rare cause of elevated transaminase levels in patients with UC. The best treatment to control the 2 conditions should be evaluated with vigilance for the side effects of medications, mainly infections, especially in patients with cirrhosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interests to disclose.

Figures

Figure 1.
Figure 1.
Sigmoidoscopy images showing severe ulcerative colitis, mucosal edema and erythema, friability, and spontaneous bleeding, compatible with a Mayo endoscopic score of 3.
Figure 2.
Figure 2.
Chest radiograph showing pulmonary bilateral diffuse infiltrates.
See this image and copyright information in PMC

References

    1. Magro F, Gionchetti P, Eliakim R, et al. . Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–70. [Erratum in: J Crohns Colitis. 2022 Aug 16]. - PubMed
    1. Harbord M, Annese V, Vavricka SR, et al. . The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–54. - PMC - PubMed
    1. Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19:7327–40. - PMC - PubMed
    1. Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic association for the study of the liver clinical practice guidelines: autoimmune hepatitis. Ann Gastroenterol. 2019;32:1–23. - PMC - PubMed
    1. Mack CL, Adams D, Assis DN, et al. . Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology. 2020;72:671–722. - PubMed

Publication types

MeSH terms